Stokes Capital Advisors LLC Acquires 1,620 Shares of Amgen Inc. $AMGN

Stokes Capital Advisors LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 236.2% during the 1st quarter, Holdings Channel reports. The institutional investor owned 2,306 shares of the medical research company’s stock after acquiring an additional 1,620 shares during the quarter. Stokes Capital Advisors LLC’s holdings in Amgen were worth $811,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in AMGN. Vanguard Group Inc. boosted its position in Amgen by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after purchasing an additional 961,975 shares during the last quarter. State Street Corp increased its position in shares of Amgen by 4.4% during the 4th quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after purchasing an additional 1,287,310 shares during the last quarter. Capital World Investors raised its stake in shares of Amgen by 22.9% during the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares in the last quarter. Capital International Investors raised its stake in shares of Amgen by 1.5% during the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after purchasing an additional 282,219 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Amgen by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after buying an additional 1,035,779 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $352.82 on Friday. The company’s 50 day moving average price is $340.49 and its two-hundred day moving average price is $346.11. Amgen Inc. has a 12-month low of $269.77 and a 12-month high of $391.29. The firm has a market cap of $190.42 billion, a PE ratio of 24.55, a PEG ratio of 3.53 and a beta of 0.42. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last announced its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The company had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. During the same period last year, the firm earned $4.90 earnings per share. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities research analysts predict that Amgen Inc. will post 22.38 earnings per share for the current year.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This trade represents a 15.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.85% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a report on Thursday, June 18th. Erste Group Bank restated a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Guggenheim dropped their target price on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a report on Monday, May 4th. Leerink Partners reiterated a “market perform” rating and issued a $355.00 target price on shares of Amgen in a research note on Thursday, March 5th. Finally, The Goldman Sachs Group set a $389.00 price target on Amgen in a report on Friday, June 5th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Amgen presently has a consensus rating of “Hold” and an average price target of $354.42.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.